Thermal Stability, Plasma Pharmacokinetics, and Tumor Response Modeling of a Cell-Penetrating Protein That Cleaves RAS Family GTPases
Authors:
- 20 August 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2639-2653
Abstract
RRSP–RBD–TAT is a cell-penetrating fusion protein composed of a RAS/Rap1-specific endopeptidase (RRSP), a RAS-binding domain (RBD), and a transactivator-of-transcription (TAT) cell-permeable peptide. It catalytically and irreversibly cleaves RAS family proteins and has shown potent antitumor activity. To advance this unconventional intracellular protein therapeutic toward translation, we characterized its thermal stability, developed a capillary-based Simple Western immunoassay for quantitative blood analysis, measured plasma pharmacokinetics and tumor-associated exposure, and linked these measurements to intratumoral signaling and tumor response. RRSP–RBD–TAT retained its secondary structure and anticancer activity for 3 days at 20–37 °C, whereas temperatures above approximately 50 °C caused rapid unfolding, aggregation, and irreversible loss of activity. The Simple Western assay separated immunoreactive RRSP–RBD–TAT from the albumin-rich region of serum and plasma, enabling quantitative concentration–time profiling after intravenous administration. Following a single 50 mg/kg dose, plasma concentrations declined rapidly with a biexponential profile, whereas apparent micromolar tumor-associated concentrations were detected at 3 and 6 h. Tumors showed near-complete depletion of intact RAS and prolonged suppression of ERK phosphorylation, which persisted after tumor-associated drug levels had declined below the practical detection range. An integrated semimechanistic pharmacokinetic–pharmacodynamic–tumor growth inhibition model reproduced the observed dose-dependent responses. Exploratory human-scaled simulations revealed dose- and schedule-dependent effects and suggested that both improved intracellular potency and prolonged systemic persistence could lower the projected effective dose, with potency enhancement producing the larger shift under the current model assumptions.Keywords
Funding Information
- Naito Foundation (NA)
- Takeda Science Foundation (NA)
- Uehara Memorial Foundation (NA)
- Japan Agency for Medical Research and Development (23ck0106781h0002)
- Japan Agency for Medical Research and Development (25ck0106074h0001)
- Japan Society for the Promotion of Science (22K15246)
- Japan Society for the Promotion of Science (25K02678)
- Mochida Memorial Foundation for Medical and Pharmaceutical Research (NA)
- MSD Life Science Foundation, Public Interest Incorporated Foundation (NA)
- Nagoya University Hospital (A123)
- Support for Pioneering Research Initiated by the Next Generation (JPMJSP2125)
- Graduate Program in Physics at UNIFAL-MG (NA)
This publication has 28 references indexed in Scilit:
- Advances in Cytosolic Delivery of Proteins: Approaches, Challenges, and Emerging TechnologiesChemistry & Biodiversity, 2025
- Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domainsCell Chemical Biology, 2021
- Protein aggregation and immunogenicity of biotherapeuticsInternational Journal of Pharmaceutics, 2020
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersBioDrugs, 2015
- Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domainNature Communications, 2015
- Questioning the use of PEGylation for drug deliveryDrug Delivery and Translational Research, 2013
- Interspecies Modeling and Prediction of Human Exenatide PharmacokineticsPharmaceutical Research, 2012
- Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsJournal of Pharmacokinetics and Pharmacodynamics, 2010
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearanceAdvanced Drug Delivery Reviews, 2008
- Transit Compartments versus Gamma Distribution Function To Model Signal Transduction Processes in PharmacodynamicsJournal of Pharmaceutical Sciences, 1998